Uptravi Prices — US Pharmacy Cost vs Canada

At the US pharmacies in our data, the lowest listed discount-card price for Uptravi is around $23,548.99. Prices vary by pharmacy, dosage, and pack size, so use the table above to compare specific options near you.

Canadian pharmacy listings in our data show Uptravi priced from about $24.55 per tablet (converted to USD), before shipping. Pack size and pharmacy both affect the final total — see the Canada pricing table for specifics.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. Check the comparison table above for the specific numbers on Uptravi.

Generic and brand-name pricing for Uptravi is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.

The amount you pay for Uptravi with insurance depends significantly on your specific health plan's coverage details, its formulary status for the drug, and your current deductible or copay stage. To determine your exact cost, ask your pharmacist to process your prescription through your insurance. Many patients also investigate additional savings through prescription discount programs or manufacturer assistance programs to further lower their out-of-pocket expenses.

Many Medicare Part D and Medicare Advantage plans include Uptravi on their formularies. Your actual cost will depend on your plan's coverage phase (e.g., deductible, initial coverage, or gap) and its specific terms. Patients looking to manage out-of-pocket costs can inquire about savings options, such as pharmacy discount programs, which may offer lower prices for prescriptions filled at participating pharmacies.

No, Uptravi is currently only available as a brand-name drug. It is manufactured by Actelion Pharmaceuticals US, Inc., and there is no FDA-approved generic equivalent on the market at this time.